Christina Bailey
Microbot MedicalAbout Christina Bailey
Vice President of Sales at Microbot Medical (MBOT), appointed July 22, 2025, reporting directly to CEO/President/Chairman Harel Gadot . A two‑time U.S. Olympian with 20 years of medical device sales leadership at Boston Scientific, Abbott, Stryker, and Intuitive Surgical; previously VP of U.S. Sales at Endologix . Her remit is commercial build‑out and U.S. sales execution as MBOT transitions to commercialization following FDA 510(k) clearance of the LIBERTY Endovascular Robotic System in September 2025 [17] and completion of the commercial leadership team . Performance metrics such as TSR, revenue growth, and EBITDA growth tied specifically to her tenure are not disclosed.
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Endologix | Vice President of U.S. Sales | Not disclosed | Built/scaled sales team; achieved sales milestones in endovascular portfolio |
| Boston Scientific | Sales leadership roles | Not disclosed | Led multiple new product launches; growth and high-performing teams |
| Abbott | Sales leadership roles | Not disclosed | Broadened commercial execution and market access capabilities |
| Stryker | Sales leadership roles | Not disclosed | Enhanced market penetration in medtech portfolios |
| Intuitive Surgical | Sales leadership roles | Not disclosed | Commercial strategy for disruptive technologies |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| USA Hockey | Board Member | Not disclosed | Governance/leadership; network access across elite sports |
| U.S.A. Women’s Hockey Team | Olympian (Gold, Nagano 1998) | 1998 | Elite team leadership; recognition credentials |
Fixed Compensation
No public disclosure available for Christina Bailey’s base salary, target bonus, or equity grants. She is not listed among named executive officers in MBOT’s 2025 definitive proxy (DEF 14A) and her July 22, 2025 8‑K furnished a press release without compensatory terms .
| Component | FY 2025 | Notes |
|---|---|---|
| Base Salary | Not disclosed | Not included in 2025 DEF 14A; no compensatory 8‑K filed for Bailey |
| Target Bonus % | Not disclosed | Not disclosed in SEC filings |
| Actual Bonus Paid | Not disclosed | Not disclosed in SEC filings |
| Equity Awards (RSUs/Options) | Not disclosed | No award details disclosed for Bailey in 2025 filings |
| Perquisites | Not disclosed | No executive‑specific perquisites disclosed for Bailey |
Performance Compensation
No disclosure of performance metrics, weighting, targets, or payouts specific to Christina Bailey.
| Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|
| Not disclosed | — | — | — | — | — |
Equity Ownership & Alignment
- Beneficial ownership: Christina Bailey is not listed in MBOT’s beneficial ownership table as of April 15, 2025; she was appointed later on July 22, 2025 .
- Insider trading controls (company‑wide):
- Trading window and blackout policy; pre‑clearance required for insiders; event‑specific blackouts may be imposed .
- Hedging prohibited; margin accounts and pledging require prior approval; standing/limit orders restricted outside short window periods .
- 10b5‑1 plans permitted subject to cooling‑off periods and compliance certifications .
- Pledging/hedging: Prohibited or tightly controlled, reducing misalignment risks .
- Ownership guidelines: No executive ownership guideline disclosures in the proxy for Bailey; director compensation and grants are disclosed separately .
Employment Terms
- Appointment and reporting: Appointed VP of Sales on July 22, 2025; reports to CEO/President/Chairman .
- Contract, severance, change‑of‑control: No employment agreement or severance/change‑of‑control terms disclosed for Christina Bailey in 2025 filings. Item 5.02 disclosures in September 2025 addressed one‑time bonuses for other executives, not Bailey .
- Indemnification: MBOT maintains standard indemnification agreements and D&O insurance for directors and officers; officer coverage applies broadly but Bailey’s specific indemnification agreement is not individually disclosed .
Investment Implications
- Commercial ramp signal: The July 2025 hire and subsequent build‑out (sales director reporting directly to Bailey; sales training and marketing hires) indicate active commercialization infrastructure for the LIBERTY system after FDA clearance, supporting near‑term revenue path dependence on sales execution quality [17].
- Alignment/retention: Absence of disclosed compensation/vesting terms for Bailey limits external assessment of pay‑for‑performance alignment and retention risk; however, MBOT’s stringent insider policies (pre‑clearance, blackout controls, hedging/pledging restrictions) mitigate misalignment behaviors and reduce insider selling risk windows .
- Execution focus: Bailey’s background in launching disruptive technologies at tier‑one medtech firms and her role overseeing U.S. sales suggest emphasis on pipeline conversions, training, and customer engagement—key for limited market release and initial adoption curves .
- Monitoring priorities: Track any future 8‑K compensatory disclosures, Form 4 transactions, and annual proxy updates to assess incentive structures, vesting schedules, and ownership stakes; monitor sell‑through from limited market release and sales force productivity metrics as reported in earnings or press releases .
Key disclosures underpinning this analysis: appointment details and biography ; team build‑out and commercial leadership completion ; FDA 510(k) clearance milestone [17]; insider trading/blackout/hedging/pledging policies ; absence of Bailey compensation terms in proxies/8‑Ks ; Item 5.02 bonuses for other executives (not Bailey) .